Results 111 to 120 of about 2,423,182 (300)
Forbes Tıp DergisiObjective: Non-steroidal anti-inflammatory drug (NSAID) hypersensitivity is one of the leading causes of drug hypersensitivity in children. However, data on phenotype distribution according to the 2025 World Allergy Organization (WAO) classification and ...
Özgen SOYÖZ +8 more
doaj +1 more source
Engineering Biology Beyond Single Genes: Advances and Challenges in Multiplex Genome Editing
Animal Research and One Health, EarlyView.Multiplex genome editing is transforming genome engineering from single‐gene perturbation to network‐level control, yet its broader application remains limited by challenges in gRNA array engineering, delivery technologies, and safety management. Emerging AI‐driven approaches are accelerating guide RNA design and CRISPR effector optimization for ...
Linli Wang, Yongbin Liu, Hongbing Han
wiley +1 more source
Arthritis &Rheumatology, EarlyView.Objective The purpose of this study was to assess the pharmacokinetics, effectiveness, safety, and immunogenicity of certolizumab pegol (CZP) in polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods Pediatric Arthritis Study of Certolizumab Pegol (NCT01550003), a multicenter, open‐label study, enrolled patients aged 2 to 17 years with ...
Hermine I. Brunner +52 more
wiley +1 more source
Editorial: Women in NK and innate lymphoid cell biology
Frontiers in Immunology, 2023 Alessandra Zingoni, Teresa Bellón
doaj +1 more source
Clinical Management of Nonsteroidal Anti-inflammatory Drug Hypersensitivity
, 2008 Hypersensitivity diseases caused by nonsteroidal anti-inflammatory agents are relatively common in the population. This article summarizes the present understanding on the various allergic and nonallergic clinical pictures produced through ...
Mario Sánchez-Borges, MD
core +1 more source
Arthritis &Rheumatology, EarlyView.Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week, double‐blind, placebo‐controlled, phase 3 Program for Evaluation
Philip J. Mease +20 more
wiley +1 more source
, 2018 The dataset, which included study name, medical condition, intervention, arm titles, and adverse drug reactions, was queried for drug hypersensitivity reactions using the key terms: hypersensitivity, allergic reaction, allergy, anaphylaxis, allergic ...
Luo, Jake +9 more
core +1 more source
Arthritis &Rheumatology, EarlyView.Objective Obesity or overweight occurs in 72% to 82% of individuals with psoriatic arthritis (PsA). Previous data revealed greater disease control with concomitant ixekizumab (IXE) and tirzepatide (TZP) versus IXE alone in adults with active PsA and obesity or overweight with at least one weight‐related comorbidity at the week 36 primary end point. The
Joseph F. Merola +14 more
wiley +1 more source
Contemporary management of pain in cirrhosis: Toward precision therapy for pain
Hepatology, EarlyView., 2022 Abstract Chronic pain is highly prevalent in patients with cirrhosis and is associated with poor health‐related quality of life and poor functional status. However, there is limited guidance on appropriate pain management in this population, and pharmacologic treatment can be harmful, leading to adverse outcomes, such as gastrointestinal bleeding ...
Alexis Holman +4 more
wiley +1 more source